Medigen Biotechnology (ROCO:3176) Long-Term Debt : NT$446 Mil (As of Mar. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Medigen Biotechnology Long-Term Debt?

Medigen Biotechnology's Long-Term Debt for the quarter that ended in Mar. 2024 was NT$446 Mil.

Medigen Biotechnology's quarterly Long-Term Debt declined from Sep. 2023 (NT$459 Mil) to Dec. 2023 (NT$449 Mil) and declined from Dec. 2023 (NT$449 Mil) to Mar. 2024 (NT$446 Mil).

Medigen Biotechnology's annual Long-Term Debt increased from Dec. 2021 (NT$471 Mil) to Dec. 2022 (NT$2,129 Mil) but then declined from Dec. 2022 (NT$2,129 Mil) to Dec. 2023 (NT$449 Mil).

Medigen Biotechnology Long-Term Debt Historical Data

The historical data trend for Medigen Biotechnology's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medigen Biotechnology Long-Term Debt Chart

Medigen Biotechnology Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Debt

Get a 7-Day Free Trial

846.01

486.37

470.77

2,129.16

449.10

Medigen Biotechnology Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Long-Term Debt	Get a 7-Day Free Trial															2,130.62	467.05	459.12	449.10	445.71

Medigen Biotechnology (ROCO:3176) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Medigen Biotechnology Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Medigen Biotechnology's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Medigen Biotechnology (ROCO:3176) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medigen Biotechnology Corp (ROCO:3176) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

Yuancyu Street, 14F, Building No.3,, Nangang District, Taipei, TWN, 11560

Website

https://www.medigen.com.tw

Medigen Biotechnology Corp is a biopharmaceutical company primarily engaged in new drug development, drug discovery, molecular diagnostics, vaccine, and generic drugs. The new drug development business focuses mainly on the clinical stage of drug development and includes PI-88 MUPAFOSTAT for the treatment of liver cancer and OBP-301 treatment using adenovirus targeted to cancer cells only. Drug discovery includes the development of human-native mAbs for therapeutic applications related to infectious diseases. Generic drugs include pharmaceuticals for infectious diseases (antibiotics), contraceptives, nutrition milk powder, vitamin C tablets, dermatologic agents, and eye care products.

Medigen Biotechnology (ROCO:3176) Headlines

No Headlines